The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosal Healing in Adult Patients With Newly Diagnosed Crohn's Disease
Primary Purpose
Crohn Disease
Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Modulen
Budesonide
Sponsored by
About this trial
This is an interventional treatment trial for Crohn Disease
Eligibility Criteria
Inclusion Criteria:
- Newly diagnosed Crohn's Disease
- Mild to moderate severity
Exclusion Criteria:
- Patients who received systemic steroid or Budesonide or biological treatment
- Recent bowel surgery
- Colostomy, ileostomy
- Short bowel syndrome
- Obstructive symptoms
- Pregnancy, lactation
- Cardiac pacemaker or defibrillator
- Swallowing problems
- Uncontrolled metabolic diseases or any other condition that can be exacerbated by steroids
Sites / Locations
- Hillel Yaffe Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Modulen Diet
Budesonide Treatment
Arm Description
Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
Crohn patients will be given Budesonide treatment
Outcomes
Primary Outcome Measures
Efficacy of Modulen Diet
Patients will undergo capsular endoscopy before and after dietary intervention and mucosal healing will be accessed using standard Lewis Score. Outcome will be compared to efficacy of Budesonide treatment.
Secondary Outcome Measures
Full Information
NCT ID
NCT04233463
First Posted
January 15, 2020
Last Updated
January 15, 2020
Sponsor
Hillel Yaffe Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT04233463
Brief Title
The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosal Healing in Adult Patients With Newly Diagnosed Crohn's Disease
Official Title
The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosal Healing in Adult Patients With Newly Diagnosed Crohn's Disease: a Prospective, Randomized Study
Study Type
Interventional
2. Study Status
Record Verification Date
January 2020
Overall Recruitment Status
Unknown status
Study Start Date
January 2020 (Anticipated)
Primary Completion Date
January 2021 (Anticipated)
Study Completion Date
June 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hillel Yaffe Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to evaluate prospectively a possible effect of an oral polymeric diet enriched with TGF-beta 2 (Modulen) as compared to Budesonide (one of the commonly accepted treatments for Crohn's disease) on clinical response, mucosal healing and intestinal microbiota in adult patients with newly diagnosed Crohn's disease using a capsule endoscopy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Modulen Diet
Arm Type
Active Comparator
Arm Description
Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
Arm Title
Budesonide Treatment
Arm Type
Active Comparator
Arm Description
Crohn patients will be given Budesonide treatment
Intervention Type
Dietary Supplement
Intervention Name(s)
Modulen
Intervention Description
Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
Intervention Type
Drug
Intervention Name(s)
Budesonide
Intervention Description
Standard treatment for mild Crohn Disease patients
Primary Outcome Measure Information:
Title
Efficacy of Modulen Diet
Description
Patients will undergo capsular endoscopy before and after dietary intervention and mucosal healing will be accessed using standard Lewis Score. Outcome will be compared to efficacy of Budesonide treatment.
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Newly diagnosed Crohn's Disease
Mild to moderate severity
Exclusion Criteria:
Patients who received systemic steroid or Budesonide or biological treatment
Recent bowel surgery
Colostomy, ileostomy
Short bowel syndrome
Obstructive symptoms
Pregnancy, lactation
Cardiac pacemaker or defibrillator
Swallowing problems
Uncontrolled metabolic diseases or any other condition that can be exacerbated by steroids
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Baruch Ovadia, MD
Phone
972-545767372
Email
ovadiabaruch@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Baruch Ovadia, MD
Organizational Affiliation
Hillel Yaffe Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hillel Yaffe Medical Center
City
Hadera
ZIP/Postal Code
38100
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Baruch Ovadia, MD
Phone
972-545767372
Email
ovadiabaruch@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosal Healing in Adult Patients With Newly Diagnosed Crohn's Disease
We'll reach out to this number within 24 hrs